ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025
Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous peripheral T cell lymphomas (PTCL) are rare and show an aggressive course with limited response to therapy. The efficacy of brentuximab vedotin in cutaneous peripheral T cell lymphomas has not yet been systematically investigated. PATIENTS AND
methodsIn this retrospective analysis, we evaluated brentuximab vedotin as monotherapy or in combination therapy in patients with cutaneous CD30-positive peripheral T cell lymphoma (n = 9).
resultsOverall, the therapy showed good efficacy and acceptable tolerability. One patient achieved an almost complete response, five had a partial response, and two had a mixed response as best overall response. The median time to response was 31.5 days (interquartile range 12-53). The median duration of response was short at 4.3 months. Median overall survival from initiation of brentuximab vedotin was 15.2 months; four of nine patients died from advanced lymphoma and one patient died from an unrelated cause.
conclusionBrentuximab vedotin as monotherapy or combination therapy is a rapidly effective and tolerable treatment option for patients with cutaneous PTCL, although the duration of response is short.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.